Evidence map›Paper›PMID 28159826›Full record

Trial reportCirculation. Heart failure2017

Aortic Waveform Analysis to Individualize Treatment in Heart Failure.

Peter Wohlfahrt, Vojtech Melenovsky, Margaret M Redfield, Thomas P Olson, Grace Lin, Sahar S Abdelmoneim, Bernhard Hametner, Siegfried Wassertheurer, Barry A Borlaug

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Circulation. Heart failure, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00588692 (Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00588692 nacompletednot on this map

Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure

TypeinterventionalSponsorMayo ClinicRan2007 to 2012Enrolled60ConditionsHeart FailureArmsSphygmoCor
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Heart Failure: Insights From the Arterial Waves.Journal of the American Heart Association · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Pulse Waveform Analysis: Is It Ready for Prime Time?Current hypertension reports · 2017
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Peter WohlfahrtFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.).
Vojtech MelenovskyFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.).
Margaret M RedfieldFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.).
Thomas P OlsonFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.).
Grace LinFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.).
Sahar S AbdelmoneimFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.).
Bernhard HametnerFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.).
Siegfried WassertheurerFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.).
Barry A BorlaugFrom the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN (P.W., V.M., M.M.R., T.P.O., G.L., S.S.A., B.A.B.); International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic (P.W.); Center for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic (P.W.); Departments of Preventive Cardiology (P.W.) and Cardiology (V.M.), Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic; and Health and Environment Department, AIT Austrian Institute of Technology, Vienna, Austria (B.H., S.W.). borlaug.barry@mayo.edu.
University Hospital Brno · CZCharles University · CZSt. Anne's University Hospital Brno · CZ

Funding

HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4M
NHLBI NIH HHS R01 HL128526
6 · The paper itself

Abstract

backgroundAfterload reduction is a cornerstone in the management of patients with heart failure (HF) and reduced ejection fraction. However, arterial load and the effect of HF therapies on afterload might vary between individuals. Tailoring vasoactive medicines to patients with HF based upon better understanding of arterial afterload may enable better individualization of therapy. METHODS AND

resultsSubjects with HF and reduced ejection fraction underwent aggressive titration of vasoactive HF therapies with assessment of central aortic waveforms analyzed using pulse wave, wave separation, and arterial reservoir models. Clinical response to treatment was assessed using the 6-minute walk test distance, which increased in 25 subjects and decreased or remained unchanged in 13. Subjects with improvement on therapy displayed higher aortic pressure wave pulsatility (central pulse pressure [PP], reflected pressure wave, and reservoir pressure) at study entry compared with subjects without improvement (all P<0.05). Parameters derived by the arterial analysis methods were strongly correlated with one another and displayed similar ability to predict improvement. Aortic pressure pulsatility significantly decreased in subjects with functional improvement, whereas no change was observed in patients without functional improvement (P for interaction <0.05). These differences in arterial load at baseline and on therapy were not apparent from conventional brachial artery cuff pressure assessments.

conclusionsIncreased aortic pressure wave pulsatility and greater decrease in pulsatility on treatment are associated with functional improvement in patients with HF and reduced ejection fraction receiving aggressive vasodilator titration. These differences are not identifiable using brachial cuff pressures. Central aortic waveform analysis may enable better individualization of vasoactive therapies in chronic HF and reduced ejection fraction. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00588692.

Indexed as

AgedAged, 80 and overAortaArterial PressureChronic DiseaseExercise TestExercise ToleranceFemaleHeart FailureHumansMaleMiddle AgedMinnesotaPilot ProjectsPulsatile FlowPulse Wave AnalysisVasodilator Agentsaortaarterial pressureblood pressureheart failureheart rate

Identifiers

PMID28159826
PMCPMC5308883
OpenAlexW2892435346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.